Bellerophon Therapeutics Announces License Agreement for the Commercialization of INOpulse® in Greater China with Baylor BioSciences
Bellerophon to receive a license payment of $6 million, as well as royalties on net…
News
IMUNON Enters into Collaborative Research Agreement with The Wistar Institute’s Vaccine & Immunotherapy Center to Research IMUNON’s PLACCINE Vaccine Platform
LAWRENCEVILLE, NJ and PHILADELPHIA, PA, Jan. 05, 2023 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN),…
SELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Head of Regulatory Affairs
Andrew Elnatan Brings Nearly Three Decades of Global Regulatory Experience with Successful Breakthrough Therapy Designation…
Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults
— Breakthrough Therapy Designation for 24-Valent Investigational Pneumococcal Conjugate Vaccine Candidate Based on Positive Topline…
FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer
FREMONT, CA, Jan. 05, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:…
Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial
A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options NEW YORK, Jan….
INVECTYS, INC. TO PARTICIPATE IN THE 41st JP MORGAN HEALTHCARE CONFERENCE ON JANUARY 9-12, 2023
Houston, Texas, Jan. 05, 2023 (GLOBE NEWSWIRE) — Invectys, Inc. “Invectys”, a clinical-stage immunotherapy company…
Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
PHILADELPHIA, Jan. 05, 2023 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology…
Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer
NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) — Reset Pharmaceuticals, Inc. (Reset Pharma), a privately…
Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
– Final cohort of Phase 1 study projected to be complete in H1 2023 –…
World Orphan Drug Alliance Announces Agreement with Theratechnologies for the Distribution of EGRIFTA SV
Under the agreement, the World Orphan Drug Alliance (WODA) has obtained exclusive distribution rights to…
ORYZON to Give Updates on Corporate Progress in January
6th Sachs Annual Neuroscience Innovation Forum 12th Annual LifeSci Advisors Corporate Access Event 41st Annual…
Ventyx Biosciences to Host R&D Event on January 26, 2023
ENCINITAS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a…
Cogent Biosciences Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. and BOULDER, Colo., Jan. 05, 2023 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT),…
Intercept Pharmaceuticals to Present at J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023
MORRISTOWN, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical…
ShapeTX to Showcase Groundbreaking Advances in CNS in vivo RNA Editing, CNS-Targeting AAVs, and TruStable™ AAV Manufacturing at the J.P. Morgan 41st Annual Healthcare Conference
SEATTLE, Jan. 05, 2023 (GLOBE NEWSWIRE) — ShapeTX today announced Francois Vigneault, Ph.D., Co-founder and…
Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc….
Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial of ‘1104 in Allergic Disease
Topline data anticipated in Q2 2023 NEW ORLEANS and LOS ANGELES and LONDON, Jan. 05,…
Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield Contract
Total Procurement-related Revenue Recognition of $38.1 Million to Paratek in December 2022 Procurement Triggered by…
Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced
New round of financing led by Vensana Capital will support technology platform expansion and further…